3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
873
Neoplasms, Plasma Cell
162
Lymphoma, Non-Hodgkin
139
Lymphoma
135
Hodgkin Disease
134
Leukemia, Lymphocytic, Chronic, B-Cell
118
Precursor Cell Lymphoblastic Leukemia-Lymphoma
109
Myelodysplastic Syndromes
103
Recurrence
101
Leukemia, Myeloid, Acute
99
Leukemia
94
Lymphoma, Mantle-Cell
80
Lymphoma, Large B-Cell, Diffuse
76
Lymphoma, Follicular
73
Myeloproliferative Disorders
69
Lymphoma, B-Cell, Marginal Zone
69
Hematologic Neoplasms
64
Burkitt Lymphoma
64
Primary Myelofibrosis
57
Lymphoma, Large-Cell, Immunoblastic
55
Waldenstrom Macroglobulinemia
52
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
52
Leukemia, Myeloid, Chronic-Phase
46
Lymphoma, T-Cell, Cutaneous
44
Immunoglobulin Light-chain Amyloidosis
43
Congenital Abnormalities
43
Neoplasms
41
Leukemia, Myelomonocytic, Chronic
41
Leukemia, Myeloid, Accelerated Phase
40
Sezary Syndrome
38
Interventions
Moxifloxacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Bacteremia
×
Plasma cell
×
Clear all
NCT00398411
2015-06-29
MoxiProph
University of Cologne
Phase 3
Completed
66 enrolled
15 charts